Single Subject Neratinib in Bladder Cancer (NRR)



Status:Completed
Conditions:Cancer, Cancer, Bladder Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:7/15/2016
Start Date:July 2013
End Date:June 2014

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Single Subject Neratinib in Bladder Cancer

This study will be a single subject study to evaluate the efficacy of the HER2 kinase
inhibitor, neratinib, in a patient with metastatic bladder cancer harboring a HER2-GRB7 gene
fusion.


Inclusion Criteria:

* none

Exclusion Criteria:

* none

We have received FDA approval for a single subject Investigational New Drug (IND)
Application to treat a specific patient with the HER2 kinase inhibitor neratinib.
Therefore there is no inclusion / exclusion criteria.
We found this trial at
1
site
North Carolina Cancer Hospital (UNC)
Chapel Hill, North Carolina 27599
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials